21 June 2011
Advanced Retinal Therapy will be held in Vienna, Austria on 3 December 2011. At this event updates, trends and controversies in retinal tehrapy will be discussed in symposia, key-note lectures and a panel discussion session.
 |
16 June 2011
The National Institute for Health and Clinical Excellence (NICE) has recommended Ozurdex for the treatment of macular oedema caused by central retinal vein occlusion (CRVO). |
15 June 2011
Anticoagulation (warafin) therapy was linked to a higher risk of post vitreoretinal surgery (VRS) bleeding in comparison with antipletelet (aspirin, clopidogrel) therapy vitreoretinal.
|
28 April 2010
The Diabetic Retinopathy Clinical Research Network (DRCR.net) study, published in Ophthalmology online has shown that ranibizumab (Lucentis) injections, in combination with laser treatment has produced better vision results than in patients treated by laser alone for diabetic macular oedema (DME).
|
12 February 2010
Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina.
|
11 November 2009
The NAVILAS laser system, as reported on in the OTE Digest back in May this year ( What is Retinal Navigation? ) has been given FDA approval.
|
14 October 2009
Two Phase III studies of Lucentis (ranibizumab injection) in macular oedema due to retinal vein occlusion (RVO), have shown, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented at the Retina Congress 2009 meeting.
|
15 September 2009
Cataract surgery in patients with pre-existing AMD: Risks and Benefits
|
15 September 2009
A review of the role and efficacy of anti-VEGF therapy in macular disease
|
| 
